Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 2, 2025Liver InternationalOpen Access

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTetsu TomonariTTTetsuji TakayamaHKHiroki Kawashima

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals Atez/Bev improves overall survival in unresectable hepatocellular carcinoma, suggesting potential in CP-B patients.

Key Points

  • Atezolizumab plus Bevacizumab therapy improves overall survival in patients with Hepatocellular Carcinoma.
  • Median overall survival reached 10.3 months in Child-Pugh class B patients, indicating clinical significance.
  • Retrospective study evaluated the efficacy and safety of the treatment across 796 patients with CP-B liver function.
  • Findings highlight the need for effective therapeutic strategies for advanced hepatocellular carcinoma patients.

Cite This Study

Tomonari et al. (2025) studied this question.

synapsesocial.com/papers/692e3d796c9b3ab28c18717chttps://doi.org/10.1111/liv.70466
View Full Paper
Ask AI
Bookmark
Share